Does the media favor LYEL or IMTX?

In the previous week, Lyell Immunopharma had 1 more articles in the media than Immatics. MarketBeat recorded 3 mentions for Lyell Immunopharma and 2 mentions for Immatics. Immatics' average media sentiment score of 0.93 beat Lyell Immunopharma's score of 0.76 indicating that Immatics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyell Immunopharma 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immatics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRVS or LYEL?

In the previous week, Corvus Pharmaceuticals had 2 more articles in the media than Lyell Immunopharma. MarketBeat recorded 5 mentions for Corvus Pharmaceuticals and 3 mentions for Lyell Immunopharma. Corvus Pharmaceuticals' average media sentiment score of 1.07 beat Lyell Immunopharma's score of 0.76 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lyell Immunopharma 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AVLN or LYEL?

In the previous week, Avalyn Pharma and Avalyn Pharma both had 3 articles in the media. Lyell Immunopharma's average media sentiment score of 0.76 beat Avalyn Pharma's score of 0.48 indicating that Lyell Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lyell Immunopharma 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LYEL or SDGR?

In the previous week, Lyell Immunopharma had 2 more articles in the media than Schrodinger. MarketBeat recorded 3 mentions for Lyell Immunopharma and 1 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.88 beat Lyell Immunopharma's score of 0.76 indicating that Schrodinger is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyell Immunopharma 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Schrodinger 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Lyell Immunopharma (LYEL) Competitors

$12.92 -0.40 (-3.00%)

Closing price 04:00 PM Eastern

Extended Trading

$12.93 +0.01 (+0.08%)

As of 04:10 PM Eastern

Compare

LYEL vs. ARDX, IMTX, CRVS, AVLN, and SDGR

Should you buy Lyell Immunopharma stock or one of its competitors? MarketBeat compares Lyell Immunopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lyell Immunopharma include Ardelyx (ARDX), Immatics (IMTX), Corvus Pharmaceuticals (CRVS), Avalyn Pharma (AVLN), and Schrodinger (SDGR). These companies are all part of the "pharmaceutical products" industry.

How does Lyell Immunopharma compare to Ardelyx?

Lyell Immunopharma (NASDAQ:LYEL) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Lyell Immunopharma presently has a consensus target price of $43.00, suggesting a potential upside of 232.82%. Ardelyx has a consensus target price of $15.73, suggesting a potential upside of 208.98%. Given Lyell Immunopharma's higher probable upside, analysts clearly believe Lyell Immunopharma is more favorable than Ardelyx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Ardelyx has a net margin of -13.58% compared to Lyell Immunopharma's net margin of -794,858.12%. Ardelyx's return on equity of -38.11% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%
Ardelyx	-13.58%	-38.11%	-11.85%

66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by company insiders. Comparatively, 5.3% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Lyell Immunopharma has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Ardelyx has higher revenue and earnings than Lyell Immunopharma. Ardelyx is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40K	7,913.50	-$274.45M	-$13.80	N/A
Ardelyx	$407.32M	3.09	-$61.60M	-$0.23	N/A

In the previous week, Lyell Immunopharma had 3 more articles in the media than Ardelyx. MarketBeat recorded 3 mentions for Lyell Immunopharma and 0 mentions for Ardelyx. Lyell Immunopharma's average media sentiment score of 0.76 beat Ardelyx's score of 0.00 indicating that Lyell Immunopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Lyell Immunopharma	Positive
Ardelyx	Neutral

Summary

Ardelyx beats Lyell Immunopharma on 9 of the 16 factors compared between the two stocks.

How does Lyell Immunopharma compare to Immatics?

Lyell Immunopharma (NASDAQ:LYEL) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

In the previous week, Lyell Immunopharma had 1 more articles in the media than Immatics. MarketBeat recorded 3 mentions for Lyell Immunopharma and 2 mentions for Immatics. Immatics' average media sentiment score of 0.93 beat Lyell Immunopharma's score of 0.76 indicating that Immatics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lyell Immunopharma	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immatics has higher revenue and earnings than Lyell Immunopharma. Immatics is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40K	7,913.50	-$274.45M	-$13.80	N/A
Immatics	$54.60M	22.66	-$222.26M	-$1.99	N/A

66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 64.4% of Immatics shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by insiders. Comparatively, 3.3% of Immatics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Lyell Immunopharma currently has a consensus price target of $43.00, suggesting a potential upside of 232.82%. Immatics has a consensus price target of $20.80, suggesting a potential upside of 125.35%. Given Lyell Immunopharma's stronger consensus rating and higher probable upside, analysts plainly believe Lyell Immunopharma is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Immatics has a net margin of -572.35% compared to Lyell Immunopharma's net margin of -794,858.12%. Immatics' return on equity of -47.36% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%
Immatics	-572.35%	-47.36%	-39.35%

Lyell Immunopharma has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Comparatively, Immatics has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market.

Summary

Immatics beats Lyell Immunopharma on 9 of the 17 factors compared between the two stocks.

How does Lyell Immunopharma compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

Corvus Pharmaceuticals has higher earnings, but lower revenue than Lyell Immunopharma. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Lyell Immunopharma	$40K	7,913.50	-$274.45M	-$13.80	N/A

Corvus Pharmaceuticals has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -794,858.12%. Corvus Pharmaceuticals' return on equity of -38.92% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Corvus Pharmaceuticals had 2 more articles in the media than Lyell Immunopharma. MarketBeat recorded 5 mentions for Corvus Pharmaceuticals and 3 mentions for Lyell Immunopharma. Corvus Pharmaceuticals' average media sentiment score of 1.07 beat Lyell Immunopharma's score of 0.76 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lyell Immunopharma	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corvus Pharmaceuticals has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market.

Corvus Pharmaceuticals presently has a consensus target price of $33.33, indicating a potential upside of 136.41%. Lyell Immunopharma has a consensus target price of $43.00, indicating a potential upside of 232.82%. Given Lyell Immunopharma's higher possible upside, analysts clearly believe Lyell Immunopharma is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Corvus Pharmaceuticals beats Lyell Immunopharma on 10 of the 15 factors compared between the two stocks.

How does Lyell Immunopharma compare to Avalyn Pharma?

Avalyn Pharma (NASDAQ:AVLN) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

66.1% of Lyell Immunopharma shares are owned by institutional investors. 6.2% of Lyell Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Avalyn Pharma has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -794,858.12%. Avalyn Pharma's return on equity of 0.00% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%

Avalyn Pharma has higher earnings, but lower revenue than Lyell Immunopharma. Avalyn Pharma is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A
Lyell Immunopharma	$40K	7,913.50	-$274.45M	-$13.80	N/A

In the previous week, Avalyn Pharma and Avalyn Pharma both had 3 articles in the media. Lyell Immunopharma's average media sentiment score of 0.76 beat Avalyn Pharma's score of 0.48 indicating that Lyell Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lyell Immunopharma	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalyn Pharma presently has a consensus target price of $59.00, indicating a potential upside of 106.08%. Lyell Immunopharma has a consensus target price of $43.00, indicating a potential upside of 232.82%. Given Lyell Immunopharma's higher possible upside, analysts clearly believe Lyell Immunopharma is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Lyell Immunopharma beats Avalyn Pharma on 8 of the 13 factors compared between the two stocks.

How does Lyell Immunopharma compare to Schrodinger?

Lyell Immunopharma (NASDAQ:LYEL) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

In the previous week, Lyell Immunopharma had 2 more articles in the media than Schrodinger. MarketBeat recorded 3 mentions for Lyell Immunopharma and 1 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.88 beat Lyell Immunopharma's score of 0.76 indicating that Schrodinger is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lyell Immunopharma	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Schrodinger	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Schrodinger has a net margin of -40.61% compared to Lyell Immunopharma's net margin of -794,858.12%. Schrodinger's return on equity of -30.85% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%
Schrodinger	-40.61%	-30.85%	-15.32%

Lyell Immunopharma currently has a consensus target price of $43.00, indicating a potential upside of 232.82%. Schrodinger has a consensus target price of $20.25, indicating a potential upside of 35.00%. Given Lyell Immunopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Lyell Immunopharma is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

66.1% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 6.2% of Lyell Immunopharma shares are owned by company insiders. Comparatively, 10.1% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Schrodinger has higher revenue and earnings than Lyell Immunopharma. Schrodinger is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40K	7,913.50	-$274.45M	-$13.80	N/A
Schrodinger	$255.87M	4.33	-$103.26M	-$1.41	N/A

Lyell Immunopharma has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market. Comparatively, Schrodinger has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market.

Summary

Schrodinger beats Lyell Immunopharma on 10 of the 16 factors compared between the two stocks.

Get Lyell Immunopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LYEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LYEL vs. The Competition

Export

Metric	Lyell Immunopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$316.54M	$3.02B	$6.78B	$12.28B
Dividend Yield	N/A	2.05%	2.67%	9.36%
P/E Ratio	-0.94	20.20	27.12	23.98
Price / Sales	7,913.50	776.47	572.82	112.50
Price / Cash	N/A	57.12	29.05	48.09
Price / Book	1.11	4.19	10.65	6.14
Net Income	-$274.45M	$65.46M	$3.59B	$331.63M
7 Day Performance	-9.84%	-3.00%	-1.61%	-1.68%
1 Month Performance	1.41%	-1.26%	1.01%	-1.40%
1 Year Performance	39.83%	16.73%	23.83%	17.10%

Lyell Immunopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LYEL Lyell Immunopharma	3.8957 of 5 stars	$12.92 -3.0%	$43.00 +232.8%	+44.2%	$316.54M	$40K	N/A	270	News Coverage
ARDX Ardelyx	2.6065 of 5 stars	$5.16 +0.4%	$15.73 +204.8%	+17.9%	$1.27B	$427.68M	N/A	90	Positive News
IMTX Immatics	2.4701 of 5 stars	$9.35 +1.3%	$20.80 +122.5%	+59.8%	$1.24B	$54.60M	N/A	260	Positive News
CRVS Corvus Pharmaceuticals	2.9969 of 5 stars	$14.97 +1.8%	$33.33 +122.7%	+249.8%	$1.24B	N/A	N/A	30	Positive News Gap Down
AVLN Avalyn Pharma	4.1032 of 5 stars	$28.28 +1.6%	$59.00 +108.6%	N/A	$1.23B	N/A	N/A	51

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LYEL) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lyell Immunopharma (LYEL) Competitors

LYEL vs. ARDX, IMTX, CRVS, AVLN, and SDGR

How does Lyell Immunopharma compare to Ardelyx?

Summary

How does Lyell Immunopharma compare to Immatics?

Summary

How does Lyell Immunopharma compare to Corvus Pharmaceuticals?

Summary

How does Lyell Immunopharma compare to Avalyn Pharma?

Summary

How does Lyell Immunopharma compare to Schrodinger?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL vs. The Competition

Lyell Immunopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lyell Immunopharma (LYEL) Competitors

LYEL vs. ARDX, IMTX, CRVS, AVLN, and SDGR

How does Lyell Immunopharma compare to Ardelyx?

Do analysts prefer LYEL or ARDX?

Is LYEL or ARDX more profitable?

Do institutionals and insiders have more ownership in LYEL or ARDX?

Which has more risk & volatility, LYEL or ARDX?

Which has preferable valuation & earnings, LYEL or ARDX?

Does the media prefer LYEL or ARDX?

Summary

How does Lyell Immunopharma compare to Immatics?

Does the media favor LYEL or IMTX?

Which has better earnings and valuation, LYEL or IMTX?

Do institutionals & insiders have more ownership in LYEL or IMTX?

Do analysts rate LYEL or IMTX?

Is LYEL or IMTX more profitable?

Which has more volatility & risk, LYEL or IMTX?

Summary

How does Lyell Immunopharma compare to Corvus Pharmaceuticals?

Which has better earnings & valuation, CRVS or LYEL?

Is CRVS or LYEL more profitable?

Do insiders and institutionals believe in CRVS or LYEL?

Does the media prefer CRVS or LYEL?

Which has more risk & volatility, CRVS or LYEL?

Do analysts rate CRVS or LYEL?

Summary

How does Lyell Immunopharma compare to Avalyn Pharma?

Do insiders and institutionals believe in AVLN or LYEL?

Is AVLN or LYEL more profitable?

Which has better earnings & valuation, AVLN or LYEL?

Does the media favor AVLN or LYEL?

Do analysts rate AVLN or LYEL?

Summary

How does Lyell Immunopharma compare to Schrodinger?

Does the media favor LYEL or SDGR?

Is LYEL or SDGR more profitable?

Do analysts prefer LYEL or SDGR?

Do insiders and institutionals hold more shares of LYEL or SDGR?

Which has better valuation and earnings, LYEL or SDGR?

Which has more volatility & risk, LYEL or SDGR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL vs. The Competition

Lyell Immunopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools